D Blum1, G B Stene2, T S Solheim3, P Fayers4, M J Hjermstad5, V E Baracos6, K Fearon7, F Strasser8, S Kaasa3. 1. European Palliative Care Research Centre, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim david.blum@ntnu.no. 2. European Palliative Care Research Centre, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. 3. European Palliative Care Research Centre, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim. 4. European Palliative Care Research Centre, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. 5. European Palliative Care Research Centre, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim Department of Oncology, Regional Centre for Excellence in Palliative Care, Oslo University Hospital, Ullevål, Oslo, Norway. 6. Department of Oncology, Division of Palliative Care Medicine, University of Alberta, Alberta, Canada. 7. Clinical and Surgical Sciences (Surgery), University of Edinburgh, Royal Infirmary, Edinburgh, UK. 8. European Palliative Care Research Centre, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim Department of Internal Medicine and Palliative Center Cantonal Hospital, Oncological Palliative Medicine, Oncology, St Gallen, Switzerland.
Abstract
BACKGROUND: Weight loss limits cancer therapy, quality of life and survival. Common diagnostic criteria and a framework for a classification system for cancer cachexia were recently agreed upon by international consensus. Specific assessment domains (stores, intake, catabolism and function) were proposed. The aim of this study is to validate this diagnostic criteria (two groups: model 1) and examine a four-group (model 2) classification system regarding these domains as well as survival. PATIENTS AND METHODS: Data from an international patient sample with advanced cancer (N = 1070) were analysed. In model 1, the diagnostic criteria for cancer cachexia [weight loss/body mass index (BMI)] were used. Model 2 classified patients into four groups 0-III, according to weight loss/BMI as a framework for cachexia stages. The cachexia domains, survival and sociodemographic/medical variables were compared across models. RESULTS: Eight hundred and sixty-one patients were included. Model 1 consisted of 399 cachectic and 462 non-cachectic patients. Cachectic patients had significantly higher levels of inflammation, lower nutritional intake and performance status and shorter survival. In model 2, differences were not consistent; appetite loss did not differ between group III and IV, and performance status not between group 0 and I. Survival was shorter in group II and III compared with other groups. By adding other cachexia domains to the model, survival differences were demonstrated. CONCLUSION: The diagnostic criteria based on weight loss and BMI distinguish between cachectic and non-cachectic patients concerning all domains (intake, catabolism and function) and is associated with survival. In order to guide cachexia treatment a four-group classification model needs additional domains to discriminate between cachexia stages.
BACKGROUND:Weight loss limits cancer therapy, quality of life and survival. Common diagnostic criteria and a framework for a classification system for cancer cachexia were recently agreed upon by international consensus. Specific assessment domains (stores, intake, catabolism and function) were proposed. The aim of this study is to validate this diagnostic criteria (two groups: model 1) and examine a four-group (model 2) classification system regarding these domains as well as survival. PATIENTS AND METHODS: Data from an international patient sample with advanced cancer (N = 1070) were analysed. In model 1, the diagnostic criteria for cancer cachexia [weight loss/body mass index (BMI)] were used. Model 2 classified patients into four groups 0-III, according to weight loss/BMI as a framework for cachexia stages. The cachexia domains, survival and sociodemographic/medical variables were compared across models. RESULTS: Eight hundred and sixty-one patients were included. Model 1 consisted of 399 cachectic and 462 non-cachectic patients. Cachectic patients had significantly higher levels of inflammation, lower nutritional intake and performance status and shorter survival. In model 2, differences were not consistent; appetite loss did not differ between group III and IV, and performance status not between group 0 and I. Survival was shorter in group II and III compared with other groups. By adding other cachexia domains to the model, survival differences were demonstrated. CONCLUSION: The diagnostic criteria based on weight loss and BMI distinguish between cachectic and non-cachectic patients concerning all domains (intake, catabolism and function) and is associated with survival. In order to guide cachexia treatment a four-group classification model needs additional domains to discriminate between cachexia stages.
Authors: Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer Journal: Crit Care Med Date: 2017-02 Impact factor: 7.598
Authors: Martin Bailon-Cuadrado; Baltasar Perez-Saborido; Javier Sanchez-Gonzalez; Mario Rodriguez-Lopez; Agustin Mayo-Iscar; David Pacheco-Sanchez Journal: Int J Colorectal Dis Date: 2018-06-20 Impact factor: 2.571
Authors: Ola Magne Vagnildhaug; Trude Rakel Balstad; Sigrun Saur Almberg; Cinzia Brunelli; Anne Kari Knudsen; Stein Kaasa; Morten Thronæs; Barry Laird; Tora Skeidsvoll Solheim Journal: Support Care Cancer Date: 2017-12-22 Impact factor: 3.603
Authors: Gabriel F P Aleixo; Shlomit S Shachar; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini; Grant R Williams Journal: Oncologist Date: 2019-11-12
Authors: Martin Bailon-Cuadrado; Ekta Choolani-Bhojwani; Francisco J Tejero-Pintor; Javier Sanchez-Gonzalez; Mario Rodriguez-Lopez; Baltasar Perez-Saborido; Jose L Marcos-Rodriguez Journal: Updates Surg Date: 2017-12-08
Authors: Bhavani S Gannavarapu; Steven K M Lau; Kristen Carter; Nathan A Cannon; Ang Gao; Chul Ahn; Jeffrey J Meyer; David J Sher; Aminah Jatoi; Rodney Infante; Puneeth Iyengar Journal: J Oncol Pract Date: 2018-02-21 Impact factor: 3.840